GAITHERSBURG, Md., May 03, 2022 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cellular engineering company focused on providing enabling platform technologies for advance innovative cell research and the discovery, development and commercialization of next-generation cell therapies, announced today that the company’s management will participate in the following investor conferences:
Bank of America 2022 Healthcare Conference Presentation Wednesday, May 11 at 4:40 p.m. PTWilliam Blair 42nd Annual Growth Stock Conference Fireside Chat Wednesday, June 8 at 9:20 a.m. Center
Live and archived webcasts of the events will be available in the “Events” section of MaxCyte’s Investor Relations website at https://investors.maxcyte.com/.
MaxCyte is a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell research and the discovery, development and commercialization of next-generation cell therapies. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates the complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our flow electroporation technology, was designed to support the growing cell therapy market and can be used across the continuum of the high-growth cell therapy industry. , from discovery and development to commercialization of the next generation, cell-based medicines. The ExPERT product family includes: four instruments, ATx™, STx™, GTx™ and VLx™; a portfolio of treatment assemblies or proprietary disposables; and software protocols, all backed by a strong global intellectual property portfolio.
Copyright 2022 GlobeNewswire, Inc.